The next generation of Antiviral Therapies: Co-Led by Stichting Participatie Atriva and High-Tech Gründerfonds (HTGF), Atriva Therapeutics GmbH has received a second tranche of its running seed financing in total of € 3 Mn from Dutch, German and Canadian investors, after lead compound ATR-002 (Atriva’s antiviral MEK-Inhibitor against Influenza) has passed an important preclinical milestone paving the way to clinical development stage.
A new and particularly reliable method for marking cells can simplify research into diseases such as myocardial infarction, diabetes or Alzheimer's and reduce the use of test animals: Scientists from the University of Tübingen have developed a method by which they can target specific cell types in mice and monitor their behavior using positron emission tomography (PET). PET-based cell tracking allows scientists to observe complex life processes in the body without subjecting test animals to invasive methods.
The Freiburg-based startup SpinDiag GmbH recently closed a 1.6 Mio. EUR seed-round with three private investors. The team developed a revolutionary point-of-care screening system for testing patients for antibiotic-resistant bacteria at their admission to hospitals and almost instantly so. The seed-capital will make it feasible to bring SpinDiag’s system from its current laboratory environment to first tests in hospitals.
Scientists from the German Cancer Research Center (DKFZ), in collaboration with colleagues from Heidelberg University Hospital, have been able to visualize brain cancer using a novel MRI method. They use a simple sugar solution instead of conventional contrast agents, which can have side effects in the body.
High-Tech Gründerfonds is investing EUR 600,000 in Reutlingen-based SIGNATOPE GmbH. SIGNATOPE will use the funds to advance the development of its unique biomarker assay system, that has been established to support pharmaceutical research. The technology is based on special antibodies and allows the early detection of possible side effects during the drug development process. Thereby, the need for animal testing will be reduced while the drug becomes safer and the process more cost-efficient. SIGNATOPE has already secured a number of renowned companies as clients of the new technique.
TolerogenixX GmbH has developed a patented and clinically tested cell therapy technique for individualised immunosuppression in transplant patients. The technique enables the targeted disabling of undesired reactions caused by the immune system’s defences. As a seed stage investor, High-Tech Gründerfonds (HTGF) will finance this innovative technique and the preparations for Phase II of the clinical trial, which begins in spring 2018. Further applications of the technique include the transplantation of other organs and causal treatment of autoimmune diseases.
The Commission welcomes the adoption of its proposal for two Regulations on medical devices which establish a modernised and more robust EU legislative framework to ensure better protection of public health and patient safety.
The next generation of Antiviral Therapies: Led by Stichting Participatie Atriva together with High-Tech Gründerfonds (HTGF), Atriva Therapeutics GmbH has received seed financing from Dutch and German private investors to advance Atriva’s antiviral MEK-Inhibitors (Mitogen-activated protein kinase kinase inhibitor) against Influenza into the clinical development stage.
Researchers of Karlsruhe Institute of Technology (KIT) have developed a new fluorescence microscopy method: STEDD (Stimulation Emission Double Depletion) nanoscopy produces images of highest resolution with suppressed background. The new method yields an enhanced image quality, which is advantageous when analyzing three-dimensional, densely arranged subcellular structures. STEDD, a further development of the STED method, is now presented in Nature Photonics. (1)
ChemCon GmbH, service provider for custom development and custom manufacturing of active pharmaceutical ingredients (APIs) and fine chemicals, based in the Innovationspark (innovations park) Freiburg, Germany, celebrates its 20th anniversary. On January 29 in 1997, Dr. Raphael Vogler (CEO) and Dr. Peter Gockel (CSO), both graduates from the Albert-Ludwigs-University Freiburg, signed the partnering contract to found ChemCon. Today they count 90 members of staff, and ChemCon supplies customers of the pharmaceutical and chemical industry, biotechnology companies and research institutes worldwide.